Karl Jacoby

Importance to Hirudotherapy

Karl Jacoby is the unsung bridge between Haycraft's laboratory curiosity and modern anticoagulant pharmaceuticals. While Haycraft proved that hirudin existed, Jacoby proved that it could be extracted, stored, standardized, and given to patients. His 1902 paper in Berliner Klinische Wochenschrift described a multi-step purification: leech heads were finely ground, extracted with weak acid, precipitated with ammonium sulfate, dialyzed against running water, and finally lyophilized into a buff-colored powder. Yields were modest — about 5 mg of partially-pure hirudin per 100 leeches — but the protocol was reproducible and scalable. Jacoby's clinical work in Berlin between 1902 and 1909 represented the first systematic attempt to use a purified leech compound to treat human disease. He reported cases of resolved thrombophlebitis, prevented pulmonary embolism, and reduced surgical bleeding complications when his hirudin powder was administered to patients. Modern reviewers note that his preparations were probably only 5-10% pure hirudin, with the remainder consisting of contaminating leech proteins — yet the clinical signal was real and reproducible. Why did Jacoby's hirudin fail to dominate anticoagulant therapy after 1916? Heparin's emergence from porcine intestinal mucosa proved cheaper to produce at industrial scale, and the 1916-1918 war disrupted German leech-pharma supply chains. But Jacoby's protocol survived in academic memory and was directly cited by Fritz Markwardt at Greifswald in his 1957 purification paper that finally yielded crystalline hirudin. Without Jacoby's pioneering extraction chemistry, the path from Haycraft to the modern direct thrombin inhibitors would have been delayed by decades.